Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Despite Mixed Views On Efficacy Data, Advisory Committee Recommends Approval Of InterMune's Pirfenidone

This article was originally published in The Pink Sheet Daily

Executive Summary

InterMune's pirfenidone has a May 4 PDUFA date and would be the first drug approved for idiopathic pulmonary fibrosis.

You may also be interested in...



FDA’s Remarkable ALS Drug Approval: Call It The 'Hendeles Standard'

US FDA’s approval of Mitsubishi's Radicava (edaravone) is yet another demonstration of the agency’s flexibility for drugs to treat rare diseases – and pre-emptive action to fend off “Right to Try” laws. It is also a belated endorsement of one of the stranger votes by an FDA advisory committee member almost a decade ago.

Despite Positive Advisory Committee Vote, InterMune Gets Complete Response For Pirfenidone

FDA requests an additional efficacy trial, not surprising given that the IPF drug met the primary endpoint in only one of two Phase III trials.

Despite Positive Advisory Committee Vote, InterMune Gets Complete Response For Pirfenidone

FDA requests an additional efficacy trial, not surprising given that the IPF drug met the primary endpoint in only one of two Phase III trials.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel